Found 7 results

Author Title Type [ Year]

Filters: Author is Pasquini, M  [Clear All Filters]

2014

C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. H., Carter, S. L., Horowitz, M. M., and Antin, J. H., “Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT”, Blood, vol. 124, pp. 1372-1377, 2014.

2012

M. Pasquini, Devine, S., Mendizabal, A., Baden, L. R., Wingard, J., Lazarus, H. M., Appelbaum, F. R., Keever-Taylor, C. A., Horowitz, M. M., Carter, S., O'Reilly, R. J., and Soiffer, R., “Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy as Graft-Versus-Host Disease Prophylaxis for Patients with Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transpl”, J Clin Oncol, vol. 30, pp. 3194-3201, 2012.

C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W., Pasquini, M., MacMillan, M., Wingard, J., Waller, E., Grupp, S., McCarthy, P., Wu, J., Hu, Z., Carter, S., Horowitz, M. M., and Antin, J. H., “Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402”, in 54th Annual ASH Meeting, Atlanta, GA, 2012.

2010

C. Keever-Taylor, Devine, S., Soiffer, R., Carter, S., Pasquini, M., Hari, P., Stein, A., Lazarus, H., Linker, C., Goldstein, S., and O’Reilly, R., “Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303 (Abstract).”, in 16th Annual ISCT (International Society for Cellular Therapy) Meeting, Philadelphia, 2010.

M. Pasquini, Devine, S., Mendizabal, A., Baden, L., Wingard, J., Lazarus, H., Appelbaum, F., Keever-Taylor, C., O'Reilly, R., and Soiffer, R., “Comparative Effectiveness Analysis of CD34+ Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts on Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia (AML) in Complete Remiss (Poster).”, in BMT Tandem Meeting, Orlando, FL, 2010.

M. Pasquini, Foley, A., Carter, S., Confer, D., Horowitz, M., Gurgol, C., Giralt, S., Schilsky, R., and McCarthy, P., “Maximizing Accrual to Transplant Trials in Multiple Myeloma (MM): Lessons from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Eastern Cooperative Oncology Group (ECOG) and Cancer and Leukemia Group B (CALGB) Collaboration (Poster).”, in NCI ASCO Cancer Trials Accrual Symposium, Bethesda, MD, 2010.

2009

A. Alousi, Weisdorf, D., Logan, B., Bolanos-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S., Ho, V., Hayes-Lattin, B., Wingard, J., Horowitz, M., and Levine, J., “Etanercept, Mycophenolate, Denileukin, or Pentostatin Plus Corticosteroids for Acute Graft-Versus-Host Disease: A Randomized Phase 2 Trial from the Blood and Marrow Transplant Clinical Trials Network”, Blood, vol. 114, pp. 511-517, 2009.